|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Assessment of Hepatic Insulin Action in Obese Type 2 Diabetic Patients
1 Diabetes Research Centre, Medical Department M, Odense University Hospital, Odense
2 Department of Medical Physiology, Panum Institute, University of Copenhagen, Copenhagen, Denmark
Defects in hepatic insulin action in type 2 diabetes and its possible underlying mechanisms were assessed in euglycemic-hyperinsulinemic clamp studies, using improved tracer methods (constant specific activity technique). Ten obese diabetic patients (age 54 years, BMI 29 ± 0.5 kg/m2) and ten matched control subjects were studied at baseline (after an overnight fast) and during insulin infusions of 20- and 40-mU · m–2 · min–1. In the diabetic patients, plasma glucose levels were normalized overnight before the studies by low-dose insulin infusion. Hepatic sinusoidal insulin levels were estimated, and plasma levels of free fatty acids (FFAs) and glucagon were determined to assess the direct and indirect effects of insulin on hepatic glucose production (HGP) in type 2 diabetes. Baseline rates of HGP (86 ± 3 vs. 76 ± 3 mg · m–2 · min–1, P < 0.05) were slightly elevated in the diabetic patients compared with control subjects, despite much higher hepatic sinusoidal insulin levels (26 ± 3 vs. 12 ± 2 mU/l, P < 0.001). Consequently, a marked defect in the direct (hepatic) effect of insulin on HGP appeared to be present at low insulin levels. However, in response to a small increase in baseline hepatic sinusoidal insulin levels of 11 mU/l (26 ± 3 to 37 ± 3 mU/l, P < 0.05) in the 20-mU clamp, a marked suppression of HGP was observed in the diabetic patients (86 ± 3 to 32 ± 5 mg · m–2 · min–1, P < 0.001), despite only minimal changes in FFAs (0.33 ± 0.05 to 0.25 ± 0.05 mmol/l, NS) and glucagon (14 ± 1 to 11 ± 2 pmol/l, P < 0.05) levels, suggesting that the impairment in the direct effect of insulin can be overcome by a small increase in insulin levels. Compared with control subjects, suppression of HGP in the diabetic patients was slightly impaired in the 20-mU clamp (32 ± 5 vs. 22 ± 4 mg · m–2 · min–1, P < 0.05) but not in the 40-mU clamp (25 ± 2 vs. 21 ± 3 mg · m–2 · min–1, NS). In the 20-mU clamp, hepatic sinusoidal insulin levels in the diabetic patients were comparable with control subjects (37 ± 3 vs. 36 ± 3 mU/l, NS), whereas both FFA and glucagon levels were higher (i.e., less suppressed) and correlated with the rates of HGP (R = 0.71, P < 0.02; and R = 0.69, P < 0.05, respectively). Thus, at this insulin level impaired indirect (extrahepatic) effects of insulin seemed to prevail. In conclusion, hepatic insulin resistance is present in obese type 2 diabetic patients but is of quantitative significance only at low physiological insulin levels. Defects in both the direct and the indirect effects of insulin on HGP appear to contribute to this resistance.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Bakker, P. Sipkema, C. D.A. Stehouwer, E. H. Serne, Y. M. Smulders, V. W.M. van Hinsbergh, and E. C. Eringa Protein Kinase C {theta} Activation Induces Insulin-Mediated Constriction of Muscle Resistance Arteries Diabetes, March 1, 2008; 57(3): 706 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sorensen, M. S. Winzell, C. L. Brand, K. Fosgerau, R. W. Gelling, E. Nishimura, and B. Ahren Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired {beta}-Cell Function Diabetes, December 1, 2006; 55(12): 3463 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sorensen, C. L. Brand, S. Neschen, J. J. Holst, K. Fosgerau, E. Nishimura, and G. I. Shulman Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice. Diabetes, October 1, 2006; 55(10): 2843 - 2848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gupta, E. Park, H. Sandhu, T. Goh, V. Tchipashvili, and A. Giacca Direct and indirect effects of insulin on hepatic glucose production in diabetic depancreatized dogs during euglycemia. J. Endocrinol., September 1, 2006; 190(3): 695 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Iozzo, A. Gastaldelli, M. J. Jarvisalo, J. Kiss, R. Borra, E. Buzzigoli, A. Viljanen, G. Naum, T. Viljanen, V. Oikonen, et al. 18F-FDG Assessment of Glucose Disposal and Production Rates During Fasting and Insulin Stimulation: A Validation Study J. Nucl. Med., June 1, 2006; 47(6): 1016 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio {beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Haugaard, O. Andersen, F. Dela, J. J. Holst, H. Storgaard, M. Fenger, J. Iversen, and S. Madsbad Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic {beta}-cells Eur. J. Endocrinol., January 1, 2005; 152(1): 103 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Basu, A. Basu, C. M. Johnson, W. F. Schwenk, and R. A. Rizza Insulin Dose-Response Curves for Stimulation of Splanchnic Glucose Uptake and Suppression of Endogenous Glucose Production Differ in Nondiabetic Humans and Are Abnormal in People With Type 2 Diabetes Diabetes, August 1, 2004; 53(8): 2042 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Poulsen, J. E. Henriksen, O. Hother-Nielsen, and H. Beck-Nielsen The Combined Effect of Triple Therapy With Rosiglitazone, Metformin, and Insulin Aspart in Type 2 Diabetic Patients Diabetes Care, December 1, 2003; 26(12): 3273 - 3279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Iozzo, K. Hallsten, V. Oikonen, K. A. Virtanen, J. Kemppainen, O. Solin, E. Ferrannini, J. Knuuti, and P. Nuutila Insulin-Mediated Hepatic Glucose Uptake Is Impaired in Type 2 Diabetes: Evidence for a Relationship with Glycemic Control J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Iozzo, F. Geisler, V. Oikonen, M. Maki, T. Takala, O. Solin, E. Ferrannini, J. Knuuti, and P. Nuutila Insulin Stimulates Liver Glucose Uptake in Humans: An 18F-FDG PET Study J. Nucl. Med., May 1, 2003; 44(5): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Staehr, O. Hother-Nielsen, B. R. Landau, V. Chandramouli, J. J. Holst, and H. Beck-Nielsen Effects of Free Fatty Acids Per Se on Glucose Production, Gluconeogenesis, and Glycogenolysis Diabetes, February 1, 2003; 52(2): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gupta, H. Sandhu, T. Goh, K. Shah, S. R. Wiesenthal, H. Yoshii, V. Chong, T. K. T. Lam, C. A. Haber, W. Williams, et al. Insulin inhibits glucose production by a direct effect in diabetic depancreatized dogs during euglycemia Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1002 - E1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sjostrand, S. Gudbjornsdottir, A. Holmang, L. Lonn, L. Strindberg, and P. Lonnroth Delayed Transcapillary Transport of Insulin to Muscle Interstitial Fluid in Obese Subjects Diabetes, September 1, 2002; 51(9): 2742 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Virtanen, P. Lonnroth, R. Parkkola, P. Peltoniemi, M. Asola, T. Viljanen, T. Tolvanen, J. Knuuti, T. Ronnemaa, R. Huupponen, et al. Glucose Uptake and Perfusion in Subcutaneous and Visceral Adipose Tissue during Insulin Stimulation in Nonobese and Obese Humans J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3902 - 3910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Singhal, A. Caumo, P. E. Carey, C. Cobelli, and R. Taylor Regulation of endogenous glucose production after a mixed meal in type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E275 - E283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hawkins, I. Gabriely, R. Wozniak, K. Reddy, L. Rossetti, and H. Shamoon Glycemic Control Determines Hepatic and Peripheral Glucose Effectiveness in Type 2 Diabetic Subjects Diabetes, July 1, 2002; 51(7): 2179 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wu, D. A. Okar, C. B. Newgard, and A. J. Lange Increasing fructose 2,6-bisphosphate overcomes hepatic insulin resistance of type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E38 - E45. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |